Macrogenics IncMGNX
Price$3.60Intrinsic value$5.8061% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $175.1M+16.8% YoYTTM through 30 Jun 2026
Net Income -$14.6MTTM through 30 Jun 2026
Free Cash Flow -$65.5MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-18.4%
Operating Margin-161.1%
Net Margin-8.3%

Returns

-173.5%ROE
-18.0%ROA

Balance Sheet Health

Debt / Equity3.24x
Current Ratio1.90x
Net Debt-$154.2Mnet cash position
Cash & Equivalents$113.9M

Quality Metrics

Altman Z-Score-3.71
Piotroski F-Score2 / 9
FCF Margin-37.4%
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $149.5M
Diluted EPS-$0.22TTM
'19'20'21'22'23'24'25
FY2025: $-1.18

Dividend

No dividend

Capital Allocation

R&D Spend$140.4M
Capex Intensity1.0%

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.